Cargando…
A Phase IV Study of the Safety and Efficacy of CinnoPar(®) in Iranian Patients with Osteoporosis
The safety of teriparatide has been studied in various phase III and phase IV trials. However, a postmarketing study of the biosimilar of teriparatide, CinnoPar(®), has not been conducted on Iranian patients. This was a phase IV study conducted on osteoporotic patients who received an Iranian teripa...
Autores principales: | Jamshidi, Ahmadreza, Gharibdoost, Farhad, Sedighi, Sima, Hajiabbasi, Asghar, Salari, Amir-Hossein, Khabbazi, Alireza, Mottaghi, Peyman, Tahammoli Roudsari, Ahmad, Aghaei, Mehrdad, Shenavar Masooleh, Irandokht, Sabzvari, Araz, Anjidani, Nassim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184341/ https://www.ncbi.nlm.nih.gov/pubmed/34194720 http://dx.doi.org/10.1155/2021/7584308 |
Ejemplares similares
-
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
por: Jamshidi, Ahmadreza, et al.
Publicado: (2022) -
The Factors Affecting Bone Density in Cirrhosis
por: Hajiabbasi, Asghar, et al.
Publicado: (2015) -
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
por: Jamshidi, Ahmadreza, et al.
Publicado: (2017) -
Serum Vitamin D Status in Iranian Fibromyalgia Patients: according to the Symptom Severity and Illness Invalidation
por: Maafi, Alireza Amir, et al.
Publicado: (2016) -
Fibromyalgia diagnostic model derived from combination of American College of Rheumatology 1990 and 2011 criteria
por: Ghavidel-Parsa, Banafsheh, et al.
Publicado: (2019)